GSK to jettison half Aspen stake to fund 'reshape'
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline plans to sell around half of its 12.4% stake in South Africa's largest listed pharma company Aspen Pharmacare – worth around $890m – through a placing to institutional investors. Having closed the landmark megadeal with Novartis last week, GSK is taking the opportunity to assess strategic options. CEO Sir Andrew Witty said ahead of the close that it would be "disingenuous" to say that the Novartis transaction did not give him "options for different structures that may enhance shareholder value."
You may also be interested in...
GSK Strategy Chief: No Major M&A Likely In 2017
GSK expects further consolidation among rivals in 2017 but its own focus will remain internal, as it keeps integrating assets acquired by its product swap with Novartis and as its new CEO takes corporate control.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.